Giuseppe Nappi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10194666/publications.pdf

Version: 2024-02-01

491

all docs

480 28,901 76
papers citations h-index

491

docs citations

h-index g-index

491 19382
times ranked citing authors

149

#	Article	IF	CITATIONS
1	The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia, 2013, 33, 629-808.	3.9	6,757
2	New Appendix Criteria Open for a Broader Concept of Chronic Migraine. Cephalalgia, 2006, 26, 742-746.	3.9	846
3	Functional changes of the basal ganglia circuitry in Parkinson's disease. Progress in Neurobiology, 2000, 62, 63-88.	5.7	477
4	The International Classification of Headache Disorders, 2nd Edition (ICHD-II)—-Revision of Criteria for 8.2 <i>Medication-Overuse Headache</i> . Cephalalgia, 2005, 25, 460-465.	3.9	417
5	Postâ€ischemic brain damage: pathophysiology and role of inflammatory mediators. FEBS Journal, 2009, 276, 13-26.	4.7	370
6	Migraine and psychiatric comorbidity: a review of clinical findings. Journal of Headache and Pain, 2011, 12, 115-125.	6.0	301
7	Course of Migraine During Pregnancy and Postpartum: A Prospective Study. Cephalalgia, 2003, 23, 197-205.	3.9	296
8	Active Music Therapy in Parkinson's Disease: An Integrative Method for Motor and Emotional Rehabilitation. Psychosomatic Medicine, 2000, 62, 386-393.	2.0	282
9	Cluster Headache — Clinical Findings in 180 Patients. Cephalalgia, 1983, 3, 21-30.	3.9	249
10	Headache Temporal Patterns: Towards a Chronobiological Model. Cephalalgia, 1983, 3, 21-30.	3.9	234
11	Abnormal Modulatory Influence of Diffuse Noxious Inhibitory Controls in Migraine and Chronic Tension-Type Headache Patients. Cephalalgia, 2006, 26, 782-789.	3.9	234
12	Double Blind Comparison of Lithium and Verapamil in Cluster Headache Prophylaxis. Headache, 1990, 30, 411-417.	3.9	228
13	Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson's disease. Movement Disorders, 2005, 20, 1439-1448.	3.9	219
14	Magnesium Prophylaxis of Menstrual Migraine: Effects on Intracellular Magnesium. Headache, 1991, 31, 298-301.	3.9	218
15	Pain as a Nonmotor Symptom of Parkinson Disease. Archives of Neurology, 2008, 65, 1191-4.	4.5	208
16	Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Movement Disorders, 2003, 18, 685-688.	3.9	198
17	Characteristics of Menstrual and Nonmenstrual Attacks in Women with Menstrually Related Migraine Referred to Headache Centres. Cephalalgia, 2004, 24, 707-716.	3.9	188
18	Expression polymorphism of the blood???brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics and Genomics, 2002, 12, 529-534.	5.7	176

#	Article	IF	CITATIONS
19	Central Deficiency of \hat{l}^2 -Endorphin in Alcohol Addicts*. Journal of Clinical Endocrinology and Metabolism, 1982, 55, 583-586.	3.6	166
20	Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: new clues from an old model. European Journal of Neuroscience, 2007, 25, 397-405.	2.6	156
21	Early and long-term outcome of rehabilitation in stroke patients: The role of patient characteristics, time of initiation, and duration of interventions. Archives of Physical Medicine and Rehabilitation, 2003, 84, 551-558.	0.9	154
22	Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. European Journal of Human Genetics, 2006, 14, 322-331.	2.8	152
23	Naproxen Sodium in Menstrual Migraine Prophylaxis: A Double-Blind Placebo Controlled Study. Headache, 1990, 30, 705-709.	3.9	145
24	Migraine with aura and reproductive life events: a case control study. Cephalalgia, 2000, 20, 701-707.	3.9	143
25	Advice Alone Vs. Structured Detoxification Programmes for Medication Overuse Headache: A Prospective, Randomized, Open-Label Trial in Transformed Migraine Patients With Low Medical Needs. Cephalalgia, 2006, 26, 1097-1105.	3.9	137
26	Memory Functioning at Menopause: Impact of Age in Ovariectomized Women. Gynecologic and Obstetric Investigation, 1999, 47, 29-36.	1.6	136
27	Transplantation of Undifferentiated Human Mesenchymal Stem Cells Protects against 6-Hydroxydopamine Neurotoxicity in the Rat. Cell Transplantation, 2010, 19, 203-218.	2.5	136
28	Memory impairment in Cushing's disease. Acta Neurologica Scandinavica, 1993, 87, 52-55.	2.1	133
29	Multiple neurogenic and neurorescue effects of human mesenchymal stem cell after transplantation in an experimental model of Parkinson's disease. Brain Research, 2010, 1311, 12-27.	2.2	129
30	Italian guidelines for primary headaches: 2012 revised version. Journal of Headache and Pain, 2012, 13, 31-70.	6.0	129
31	Reliability of the Nitroglycerin Provocative Test in the Diagnosis of Neurovascular Headaches. Cephalalgia, 2004, 24, 110-119.	3.9	127
32	A randomised, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic foot. Neurological Sciences, 2005, 26, 26-31.	1.9	125
33	The brain as a target for adrenocortical steroids: Cognitive implications. Psychoneuroendocrinology, 1992, 17, 343-354.	2.7	124
34	Weather Interference on Cluster Headache Temporal Pattern. A Cooperative International Long-Term Study. Cephalalgia, 1989, 9, 195-196.	3.9	123
35	The Effect of Intranasal Cocaine and Lidocaine on Nitroglycerinâ€Induced Attacks in Cluster Headache. Cephalalgia, 2000, 20, 85-91.	3.9	123
36	Lamotrigine in the treatment of SUNCT syndrome. Neurology, 2001, 57, 1723-1725.	1.1	120

#	Article	IF	CITATIONS
37	Stimulation of corticotrophin-releasing hormone release by the obese (ob) gene product, leptin, from hypothalamic explants. NeuroReport, 1997, 8, 1131-1134.	1.2	119
38	Effects of diffuse noxious inhibitory controls on temporal summation of the RIII reflex in humans. Pain, 2004, 112, 353-360.	4.2	118
39	REM sleep behavior disorder, hallucinations, and cognitive impairment in Parkinson's disease. Movement Disorders, 2006, 21, 462-466.	3.9	118
40	Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease. Experimental Neurology, 2004, 187, 455-459.	4.1	114
41	Sensitisation of spinal cord pain processing in medication overuse headache involves supraspinal pain control. Cephalalgia, 2010, 30, 272-284.	3.9	114
42	Classification of Chronic Daily Headache by International Headache Society Criteria: Limits and New Proposals. Cephalalgia, 1995, 15, 37-43.	3.9	113
43	Psychiatric Comorbidity and Psychosocial Stress in Patients with Tension-Type Headache From Headache Centers in Italy. Cephalalgia, 1999, 19, 159-164.	3.9	113
44	Deep brain stimulation and cognitive functions in Parkinson's disease: A threeâ€year controlled study. Movement Disorders, 2009, 24, 1621-1628.	3.9	113
45	Hallucinations and sleep-wake cycle in PD. Neurology, 2002, 59, 1979-1981.	1.1	112
46	?Off? painful dystonia in Parkinson's disease treated with botulinum toxin. Movement Disorders, 1995, 10, 333-336.	3.9	111
47	Oral Sumatriptan: Effect of a Second Dose, and Incidence and Treatment of Headache Recurrences. Cephalalgia, 1994, 14, 330-338.	3.9	109
48	An assessment of hypothalamo-pituitary-adrenal axis functioning in non-depressed, early abstinent alcoholics. Psychoneuroendocrinology, 1996, 21, 263-275.	2.7	108
49	A consensus protocol for the management of medication-overuse headache: Evaluation in a multicentric, multinational study. Cephalalgia, 2014, 34, 645-655.	3.9	108
50	Cervicogenic Headache: Evaluation of the Original Diagnostic Criteria. Cephalalgia, 2001, 21, 573-583.	3.9	106
51	Disability, anxiety and depression associated with medication-overuse headache can be considerably reduced by detoxification and prophylactic treatment. Results from a multicentre, multinational study (COMOESTAS project). Cephalalgia, 2014, 34, 426-433.	3.9	106
52	Placebo-Controlled Comparison of Effervescent Acetylsalicylic Acid, Sumatriptan and Ibuprofen in the Treatment of Migraine Attacks. Cephalalgia, 2004, 24, 947-954.	3.9	105
53	Clinical features of migraine aura: Results from a prospective diary-aided study. Cephalalgia, 2017, 37, 979-989.	3.9	105
54	Efficacy and Tolerability in Migraine Prophylaxis of Flunarizine in Reduced Doses: A Comparison with Propranolol 160 Mg Daily. Cephalalgia, 2002, 22, 209-221.	3.9	103

#	Article	lF	CITATIONS
55	Botulinum toxin and neuromotor rehabilitation: An integrated approach to idiopathic cervical dystonia. Movement Disorders, 2006, 21, 2240-2243.	3.9	103
56	Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study. Journal of Headache and Pain, 2011, 12, 427-433.	6.0	100
57	Plasma Homocysteine and I-DOPA Metabolism in Patients with Parkinson Disease. Clinical Chemistry, 2001, 47, 1102-1104.	3.2	98
58	Nitroglycerin induces hyperalgesia in rats—a time-course study. European Journal of Pharmacology, 2003, 464, 159-162.	3.5	98
59	Spontaneous Intracranial Hypotension Syndrome: Report of Twelve Cases. Headache, 2004, 44, 615-622.	3.9	98
60	Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease. Neurobiology of Disease, 2008, 29, 161-168.	4.4	96
61	Autosomal dominant external ophthalmoplegia and bipolar affective disorder associated with a mutation in the ANT1 gene. Neuromuscular Disorders, 2003, 13, 162-165.	0.6	95
62	Duodenal Levodopa Infusion Improves Quality of Life in Advanced Parkinson's Disease. Neurodegenerative Diseases, 2008, 5, 244-246.	1.4	93
63	Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease. Neurobiology of Disease, 2006, 22, 1-9.	4.4	92
64	Postprandial and orthostatic hypotension in Parkinson's disease. Neurology, 1987, 37, 386-386.	1.1	92
65	The Association of Menstrual Migraine with the Premenstrual Syndrome. Cephalalgia, 1993, 13, 422-425.	3.9	91
66	Primary Headaches: Reduced Circulating \hat{l}^2 -Lipotropin and \hat{l}^2 -Endorphin Levels with Impaired Reactivity to Acupuncture. Cephalalgia, 1981, 1, 195-201.	3.9	88
67	Peripheral proteasome and caspase activity in Parkinson disease and Alzheimer disease. Neurology, 2006, 66, 529-534.	1.1	88
68	ICHD-II Diagnostic Criteria for Tolosa—Hunt Syndrome in Idiopathic Inflammatory Syndromes of the Orbit and/or the Cavernous Sinus. Cephalalgia, 2008, 28, 577-584.	3.9	87
69	Unbalanced Randomization Influences Placebo Response: Scientific Versus Ethical Issues Around the Use of Placebo in Migraine Trials. Cephalalgia, 1999, 19, 699-700.	3.9	86
70	Familial basilar migraine associated with a new mutation in the ATP1A2 gene. Neurology, 2005, 65, 1826-1828.	1.1	86
71	Electrophysiologic patterns of oral-pharyngeal swallowing in parkinsonian syndromes. Neurology, 2007, 68, 583-589.	1.1	85
72	REM behavior disorder, hallucinations and cognitive impairment in Parkinson's disease: A twoâ€ y ear follow up. Movement Disorders, 2008, 23, 1441-1445.	3.9	85

#	Article	IF	CITATIONS
73	The Nociceptive Flexion Reflex as a Tool for Exploring Pain Control Systems in Headache and Other Pain Syndromes. Cephalalgia, 1993, 13, 21-27.	3.9	84
74	Clinical and genetic studies in hereditary spastic paraplegia with thin corpus callosum. Neurology, 2004, 62, 262-268.	1.1	82
75	The effects on the central nervous system of nitroglycerinâ€"putative mechanisms and mediators. Progress in Neurobiology, 1999, 57, 607-624.	5.7	81
76	Progressive impairment of CSF β-EP levels in migraine sufferers. Pain, 1984, 18, 127-133.	4.2	80
77	Comparative Study with EMG, Pressure Algometry and Manual Palpation in Tension-Type Headache and Migraine. Cephalalgia, 1994, 14, 451-457.	3.9	78
78	Electrophysiological evidence for trigeminal neuron sensitization in patients with migraine. Neuroscience Letters, 2002, 317, 135-138.	2.1	77
79	Disordered pupil reactivity in Parkinson's disease. Clinical Autonomic Research, 1991, 1, 55-58.	2.5	76
80	Parthenolide is the Component of Tanacetum Parthenium that Inhibits Nitroglycerin-Induced Fos Activation: Studies in an Animal Model of Migraine. Cephalalgia, 2005, 25, 612-621.	3.9	76
81	Accompanying Symptoms of Cluster Attacks: Their Relevance to the Diagnostic Criteria. Cephalalgia, 1992, 12, 165-168.	3.9	75
82	Functional and neurochemical changes of the gastrointestinal tract in a rodent model of Parkinson's disease. Neuroscience Letters, 2009, 467, 203-207.	2.1	75
83	Pisa syndrome in Parkinson's disease: Clinical, electromyographic, and radiological characterization. Movement Disorders, 2012, 27, 227-235.	3.9	75
84	Comorbid disorders and hospitalisation in Parkinson?s disease: a prospective study. Neurological Sciences, 2004, 25, 66-71.	1.9	73
85	Dementia of the Alzheimer type and hypothalamus-pituitary-adrenocortical axis: changes in cerebrospinal fluid corticotropin releasing factor and plasma cortisol levels. Acta Neurologica Scandinavica, 1990, 81, 452-456.	2.1	72
86	Diaries and Calendars for Migraine. A Review. Cephalalgia, 2006, 26, 905-916.	3.9	71
87	Nutrition and cognitive deficit in the elderly: a population study. European Journal of Clinical Nutrition, 2001, 55, 1053-1058.	2.9	70
88	Prevalence, Pattern and Predictors of use of Complementary and Alternative Medicine (CAM) in Migraine Patients Attending a Headache Clinic in Italy. Cephalalgia, 2005, 25, 493-506.	3.9	70
89	Short-term effectiveness of simple advice as a withdrawal strategy in simple and complicated medication overuse headache. European Journal of Neurology, 2011, 18, 396-401.	3.3	70
90	Hormone Supplementation Differently Affects Migraine in Postmenopausal Women. Headache, 2002, 42, 924-929.	3.9	69

#	Article	IF	Citations
91	Advice alone versus structured detoxification programmes for complicated medication overuse headache (MOH): a prospective, randomized, open-label trial. Journal of Headache and Pain, 2013, 14, 10.	6.0	68
92	Lithium Carbonate in Cluster Headache: Assessment of Its Short- and Long-Term Therapeutic Efficacy. Cephalalgia, 1983, 3, 109-114.	3.9	67
93	Medication Overuse Headache: Predictors and Rates of Relapse in Migraine Patients With Low Medical Needs. A 1-Year Prospective Study. Cephalalgia, 2008, 28, 1196-1200.	3.9	67
94	BDNF Val66Met polymorphism is associated with cognitive impairment in Italian patients with Parkinson's disease. European Journal of Neurology, 2009, 16, 1240-1245.	3.3	67
95	An epidemiological approach to the nosography of chronic daily headache. Cephalalgia, 1993, 13, 72-77.	3.9	66
96	Subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease. Annals of Neurology, 2001, 49, 525-529.	5.3	65
97	Sunct Syndrome Successfully Treated with Topiramate: Case Reports. Cephalalgia, 2003, 23, 998-1000.	3.9	65
98	International Headache Society Classification: Interobserver Reliability in the Diagnosis of Primary Headaches. Cephalalgia, 1994, 14, 16-20.	3.9	64
99	Effects of CGRP receptor antagonism in nitroglycerin-induced hyperalgesia. Cephalalgia, 2014, 34, 594-604.	3.9	64
100	Hypnic headache. Neurology, 2004, 62, 1411-1413.	1.1	63
101	Effects of acute and chronic restraint stress on nitroglycerin-induced hyperalgesia in rats. Neuroscience Letters, 2005, 383, 7-11.	2.1	63
102	Peripheral Levels of BDNF and NGF in Primary Headaches. Cephalalgia, 2006, 26, 136-142.	3.9	63
103	Safety and efficacy of perampanel in advanced Parkinson's disease: A randomized, placebo-controlled study. Movement Disorders, 2010, 25, 896-905.	3.9	63
104	Concomitant increase in nociceptive flexion reflex threshold and plasma opioids following transcutaneous nerve stimulation. Pain, 1984, 19, 295-303.	4.2	62
105	Risk factors in medication-overuse headache: A 1-year follow-up study (care II protocol). Cephalalgia, 2010, 30, 329-336.	3.9	62
106	Serotoninergic Agonists Increase Plasma Levels of \hat{l}^2 -Endorphin and \hat{l}^2 -Lipotropin in Humans*. Journal of Clinical Endocrinology and Metabolism, 1984, 59, 1138-1142.	3.6	61
107	Circadian variations of human flexion reflex. Pain, 1986, 25, 403-410.	4.2	61
108	Novel parkin mutations detected in patients with early-onset Parkinson's disease. Movement Disorders, 2005, 20, 424-431.	3.9	60

#	Article	IF	CITATIONS
109	Oral sumatriptan compared with placebo in the acute treatment of migraine. Journal of Neurology, 1993, 241, 138-144.	3.6	59
110	The potential protective effect of tramiprosate (homotaurine) against Alzheimer's disease: a review. Aging Clinical and Experimental Research, 2012, 24, 580-7.	2.9	59
111	Different patterns of central and peripheral Î ² EP, Î ² LPH and ACTH throughout life. Peptides, 1983, 4, 469-474.	2.4	58
112	Headache and Quality of Life. Headache, 1995, 35, 29-35.	3.9	58
113	Modifications of apoptosis-related protein levels in lymphocytes of patients with Parkinson?s disease. The effect of dopaminergic treatment. Journal of Neural Transmission, 2004, 111, 1017-30.	2.8	58
114	Triptan nonresponders: Do they exist and who are they?. Cephalalgia, 2013, 33, 891-896.	3.9	58
115	Role of calcitonin gene-related peptide and substance P in different models of pain. Cephalalgia, 2008, 28, 114-26.	3.9	58
116	Familyâ€based association study of 5â€HTTLPR, TPH, MAOâ€A, and DRD4 polymorphisms in mood disorders. American Journal of Medical Genetics Part A, 2002, 114, 361-369.	2.4	57
117	Dopaminergic modulation of oxidative stress and apoptosis in human peripheral blood lymphocytes: evidence for a D1-like receptor-dependent protective effect. Free Radical Biology and Medicine, 2004, 36, 1233-1240.	2.9	57
118	A narrative review on the management of medication overuse headache: the steep road from experience to evidence. Journal of Headache and Pain, 2009, 10, 407-417.	6.0	57
119	Diagnostic Delay and Suboptimal Management in a Referral Population With Hemicrania Continua. Headache, 2009, 49, 227-234.	3.9	57
120	Cerebrospinal fluid norepinephrine, 3-methoxy-4-hydroxyphenylglycol and neuropeptide Y levels in Parkinson's disease, multiple system atrophy and dementia of the Alzheimer type. Journal of Neural Transmission Parkinson's Disease and Dementia Section, 1992, 4, 191-205.	1.2	56
121	A basic diagnostic headache diary (BDHD) is well accepted and useful in the diagnosis of headache. A multicentre European and Latin American study. Cephalalgia, 2011, 31, 1549-1560.	3.9	56
122	Single High-Dose Steroid Treatment in Episodic Cluster Headache. Cephalalgia, 2005, 25, 290-295.	3.9	55
123	βâ€Endorphin cerebrospinal fluid decrease in untreated parkinsonian patients. Neurology, 1985, 35, 1371-1371.	1.1	55
124	Premenstrual fall of plasma \hat{i}^2 -endorphin in patients with premenstrual syndrome. Fertility and Sterility, 1987, 47, 570-573.	1.0	54
125	PRKAR1B mutation associated with a new neurodegenerative disorder with unique pathology. Brain, 2014, 137, 1361-1373.	7.6	54
126	Cluster Headache in Women: Clinical Findings and Relationship with Reproductive Life. Cephalalgia, 1988, 8, 37-44.	3.9	53

#	Article	IF	CITATIONS
127	Estradiol reduces cytochrome c translocation and minimizes hippocampal damage caused by transient global ischemia in rat. Neuroscience Letters, 2004, 368, 87-91.	2.1	53
128	Biomarkers of oxidation, inflammation and cartilage degradation in osteoarthritis patients undergoing sulfur-based spa therapies. Clinical Biochemistry, 2010, 43, 973-978.	1.9	52
129	Alterations of the endocannabinoid system in an animal model of migraine: Evaluation in cerebral areas of rat. Cephalalgia, 2010, 30, 296-302.	3.9	52
130	Drug prescribing patterns in Parkinson's disease: a pharmacoepidemiological survey in a cohort of ambulatory patients. Pharmacoepidemiology and Drug Safety, 2002, 11, 149-157.	1.9	51
131	Botulinum toxin type A potentiates the effect of neuromotor rehabilitation of Pisa syndrome in Parkinson disease: A placebo controlled study. Parkinsonism and Related Disorders, 2014, 20, 1140-1144.	2.2	51
132	Guillain-Barr� syndrome: an Italian multicentre case-control study. Neurological Sciences, 2000, 21, 229-234.	1.9	50
133	Effects of peripheral FAAH blockade on NTG-induced hyperalgesia—evaluation of URB937 in an animal model of migraine. Cephalalgia, 2015, 35, 1065-1076.	3.9	50
134	Activation of the Transcription Factor NF-κB in the Nucleus Trigeminalis Caudalis in an Animal Model of Migraine. NeuroToxicology, 2005, 26, 795-800.	3.0	49
135	Homocysteine and Parkinson's disease: A dangerous liaison?. Journal of the Neurological Sciences, 2007, 257, 31-37.	0.6	49
136	Acute Reduction of Anandamideâ∈Hydrolase (FAAH) Activity is Coupled With a Reduction of Nociceptive Pathways Facilitation in Medicationâ€Overuse Headache Subjects After Withdrawal Treatment. Headache, 2012, 52, 1350-1361.	3.9	49
137	Diagnostic and therapeutic errors in cluster headache: a hospital-based study. Journal of Headache and Pain, 2014, 15, 56.	6.0	49
138	Intracerebral vascular changes induced by cold pressor test: A model of sympathetic activation. Neurological Research, 1994, 16, 163-167.	1.3	48
139	Pupillary and cardiovascular responses to the cold-pressor test. Journal of the Autonomic Nervous System, 1995, 55, 45-49.	1.9	48
140	Is seborrhea a sign of autonomic impairment in Parkinson's disease?. Journal of Neural Transmission, 1997, 104, 1295-1304.	2.8	48
141	Effects of Sleep on Spinal Nociceptive Reflexes in Humans. Sleep, 2001, 24, 13-17.	1.1	48
142	Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson's disease. Brain Research Bulletin, 2010, 82, 29-38.	3.0	48
143	Impact of headache disorders in Italy and the public-health and policy implications: a population-based study within the Eurolight Project. Journal of Headache and Pain, 2015, 16, 100.	6.0	48
144	Migraine aura symptoms: Duration, succession and temporal relationship to headache. Cephalalgia, 2016, 36, 413-421.	3.9	48

#	Article	IF	CITATIONS
145	The added value of an electronic monitoring and alerting system in the management of medication-overuse headache: A controlled multicentre study. Cephalalgia, 2017, 37, 1115-1125.	3.9	48
146	Central acth deficit in degenerative and vascular demetria. Life Sciences, 1984, 35, 1691-1697.	4.3	47
147	Dietary and nutritional patterns in an elderly rural population in Northern and Southern Italy: (I). A cluster analysis of food consumption. European Journal of Clinical Nutrition, 2003, 57, 1514-1521.	2.9	47
148	Antioxidant Effect of Sulphurous Thermal Water on Human Neutrophil Bursts: Chemiluminescence Evaluation. Respiration, 2008, 75, 193-201.	2.6	47
149	Medication Overuse Headache and Applicability of the ICHD-II Diagnostic Criteria: 1-Year Follow-Up Study (CARE I Protocol). Cephalalgia, 2009, 29, 233-243.	3.9	47
150	Diagnostic and therapeutic errors in trigeminal autonomic cephalalgias and hemicrania continua: a systematic review. Journal of Headache and Pain, 2013, 14, 14.	6.0	47
151	Poor patient awareness and frequent misdiagnosis of migraine: findings from a large transcontinental cohort. European Journal of Neurology, 2020, 27, 536-541.	3.3	47
152	Decreased high density lipoprotein-cholesterol levels in male patients with transient ischemic attacks. Atherosclerosis, 1979, 32, 205-211.	0.8	46
153	Impairment of corneal pain perception in cluster headache. Pain, 1991, 47, 299-304.	4.2	46
154	Effects of hypnosis on diffuse noxious inhibitory controls. Physiology and Behavior, 2000, 69, 295-300.	2.1	46
155	Two patients with COMT inhibitor-induced hepatic dysfunction and UGT1A9 genetic polymorphism. Neurology, 2005, 65, 1820-1822.	1.1	46
156	Dysphagia in multiple sclerosis: from pathogenesis to diagnosis. Neurological Sciences, 2008, 29, 360-363.	1.9	46
157	Neurochemical mechanisms of nitroglycerin-induced neuronal activation in rat brain: A pharmacological investigation. Neuropharmacology, 1997, 36, 1417-1424.	4.1	45
158	Botulinum toxin treatment for functional disability induced by essential tremor. Neurological Sciences, 2000, 21, 349-353.	1.9	45
159	<i>SPG3A</i> . Neurology, 2002, 59, 2002-2005.	1.1	45
160	Antioxidative effects of sulfurous mineral water: protection against lipid and protein oxidation. European Journal of Clinical Nutrition, 2009, 63, 106-112.	2.9	45
161	An Opposite-Direction Modulation of the COMT Val158Met Polymorphism on the Clinical Response to Intrathecal Morphine and Triptans. Journal of Pain, 2013, 14, 1097-1106.	1.4	45
162	Peripheral markers of oxidative stress in Parkinson's disease. the role of L-DOPA. Free Radical Biology and Medicine, 1999, 27, 428-437.	2.9	44

#	Article	IF	CITATIONS
163	Peripheral inflammation and neuroprotection: Systemic pretreatment with complete Freund's adjuvant reduces 6-hydroxydopamine toxicity in a rodent model of Parkinson's disease. Neurobiology of Disease, 2006, 24, 492-505.	4.4	43
164	Oxidative stress and pro-apoptotic conditions in a rodent model of Wilson's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2005, 1741, 325-330.	3.8	42
165	Proposals for New Standardized General Diagnostic Criteria for the Secondary Headaches. Cephalalgia, 2009, 29, 1331-1336.	3.9	42
166	Quantitative study of mitochondrial complex I in platelets of parkinsonian patients. Movement Disorders, 1998, 13, 11-15.	3.9	41
167	Endotoxin stimulates an endogenous pathway regulating corticotropin-releasing hormone and vasopressin release involving the generation of nitric oxide and carbon monoxide. Journal of Neuroimmunology, 1998, 86, 104-109.	2.3	41
168	Tolerability of the Triptans. Drug Safety, 2003, 26, 93-107.	3.2	41
169	Peripheral expression of key regulatory kinases in Alzheimer's disease and Parkinson's disease. Neurobiology of Aging, 2011, 32, 2142-2151.	3.1	41
170	Variability of the characteristics of a migraine attack within patients. Cephalalgia, 2016, 36, 825-830.	3.9	41
171	Reduced Testosterone Levels in Cluster Headache: A Stress-Related Phenomenon?. Cephalalgia, 1986, 6, 29-34.	3.9	40
172	Prostaglandins, glutamate and nitric oxide synthase mediate nitroglycerin-induced hyperalgesia in the formalin test. European Journal of Pharmacology, 2006, 534, 103-107.	3.5	40
173	3D Kinematic Analysis and Clinical Evaluation of Neck Movements in Patients with Whiplash Injury. Cephalalgia, 2002, 22, 533-542.	3.9	39
174	A Novel ATP1A2 Mutation in a Family with FHM Type II. Cephalalgia, 2006, 26, 324-328.	3.9	39
175	Use of Complementary and Alternative Medicine by Patients With Chronic Tension-Type Headache: Results of a Headache Clinic Survey. Headache, 2006, 46, 622-631.	3.9	39
176	The wolframin His611Arg polymorphism influences medication overuse headache. Neuroscience Letters, 2007, 424, 179-184.	2.1	39
177	Effect of Sex and Estrogens on Neuronal Activation in an Animal Model of Migraine. Headache, 2013, 53, 288-296.	3.9	39
178	Effects of kynurenic acid analogue 1 (KYNA-A1) in nitroglycerin-induced hyperalgesia: Targets and anti-migraine mechanisms. Cephalalgia, 2017, 37, 1272-1284.	3.9	39
179	Changes in the 24-Hour Prolactin Pattern in Cluster Headache. Cephalalgia, 1982, 2, 1-7.	3.9	38
180	Usefulness of computerized electroencephalography in diagnosing, staging and monitoring AIDS-dementia complex. Aids, 1989, 3, 209-214.	2.2	38

#	Article	IF	CITATIONS
181	Monoamines and related metabolite levels in the cerebrospinal fluid of patients with dementia of Alzheimer type. Influence of treatment with L-deprenyl. Journal of Neural Transmission Parkinson's Disease and Dementia Section, 1991, 3, 15-25.	1.2	38
182	Effects of anandamide in migraine: data from an animal model. Journal of Headache and Pain, 2011, 12, 177-183.	6.0	38
183	The Neuropharmacology of Cluster Headache and other Trigeminal Autonomic Cephalalgias. Current Neuropharmacology, 2015, 13, 304-323.	2.9	38
184	Electroencephalography in the Early Diagnosis of HIV-Related Subacute Encephalitis: Analysis of 185 Patients. Clinical EEG (electroencephalography), 1989, 20, 1-5.	0.9	37
185	High-Dose Ropinirole in Advanced Parkinson's Disease With Severe Dyskinesias. Clinical Neuropharmacology, 2003, 26, 146-150.	0.7	37
186	Inducible nitric oxide synthase is involved in the mechanisms of cocaine enhanced neuronal apoptosis induced by HIV-1 gp120 in theneocortex of rat. Neuroscience Letters, 2004, 356, 183-186.	2.1	37
187	Stimulating Effect of HIV-1 Coat Protein gp120 on Corticotropin-Releasing Hormone and Arginine Vasopressin in the Rat Hypothalamus: Involvement of Nitric Oxide. Experimental Neurology, 2000, 166, $376-384$.	4.1	36
188	Peripheral and Central Activation of Trigeminal Pain Pathways in Migraine: Data From Experimental Animal Models. Cephalalgia, 2003, 23, 1-4.	3.9	36
189	A Role for Brain Cyclooxygenaseâ€2 and Prostaglandinâ€E2 in Migraine: Effects of Nitroglycerin. International Review of Neurobiology, 2007, 82, 373-382.	2.0	36
190	Reduced Habituation of Trigeminal Reflexes in Patients with Episodic Cluster Headache During Cluster Period. Cephalalgia, 2008, 28, 950-959.	3.9	36
191	Childhood and adolescent migraine: A neuropsychiatric disorder?. Medical Hypotheses, 2011, 76, 778-781.	1.5	36
192	Temporal profile of vascular changes induced by systemic nitroglycerin in the meningeal and cortical districts. Cephalalgia, 2011, 31, 190-198.	3.9	36
193	Modulation of the human nociceptive flexion reflex by pleasant and unpleasant odors. Pain, 2013, 154, 2054-2059.	4.2	36
194	Free plasma catecholamine levels in healthy subjects: A basal and dynamic study. The influence of age. Scandinavian Journal of Clinical and Laboratory Investigation, 1992, 52, 9-17.	1.2	35
195	Estradiol supplementation modulates neuroendocrine response to M-chlorophenylpiperazine in menstrual status migrainosus triggered by oral contraception-free interval. Human Reproduction, 2005, 20, 3423-3428.	0.9	35
196	The serotonin transporter gene polymorphism STin2 VNTR confers an increased risk of inconsistent response to triptans in migraine patients. European Journal of Pharmacology, 2010, 641, 82-87.	3.5	35
197	Medicationâ€Overuse Headache and Personality: A Controlled Study by Means of the MMPlâ€2. Headache, 2010, 50, 198-209.	3.9	35
198	Illicit drug use in cluster headache patients and in the general population: A comparative cross-sectional survey. Cephalalgia, 2012, 32, 1031-1040.	3.9	35

#	Article	IF	Citations
199	Evidence for serotonin-S2 receptor involvement in analgesia in humans. European Journal of Pharmacology, 1986, 130, 311-314.	3.5	34
200	A New 5-HT2 Antagonist (Ritanserin) in the Treatment of Chronic Headache With Depression. A Double-Blind Study vs Amitriptyline. Headache, 1990, 30, 439-444.	3.9	34
201	Behavioral responses and Fos activation following painful stimuli in a rodent model of Parkinson's disease. Brain Research, 2007, 1176, 53-61.	2.2	34
202	Oral nitric-oxide donor glyceryl-trinitrate induces sensitization in spinal cord pain processing in migraineurs: A double-blind, placebo-controlled, cross-over study. European Journal of Pain, 2011, 15, 482-490.	2.8	34
203	Medication overuse headache in Europe and Latin America: general demographic and clinical characteristics, referral pathways and national distribution of painkillers in a descriptive, multinational, multicenter study. Journal of Headache and Pain, 2016, 17, 20.	6.0	34
204	Flunarizine in Common Migraine: Italian Cooperative Trial. II. Long-Term Follow-Up. Cephalalgia, 1985, 5, 155-158.	3.9	33
205	Simultaneous determination of l-dopa and 3-O-methyldopa in human platelets and plasma using high-performance liquid chromatography with electrochemical detection. Biomedical Applications, 1997, 700, 278-282.	1.7	33
206	Impaired Circadian Rhythmicity of Nociceptive Reflex Threshold in Cluster Headache. Headache, 2002, 42, 125-131.	3.9	33
207	Factors associated with a negative outcome of medication-overuse headache: A 3-year follow-up (the) Tj ETQq1 1	. 0 ₃ 784314	4 rggT /Over
208	Effectiveness of Salmon Calcitonin Nasal Spray Preparation in Migraine Treatment. Headache, 1988, 28, 196-200.	3.9	32
209	Importance of bioavailable calcium drinking water for the maintenance of bone mass in post-menopausal women. Journal of Endocrinological Investigation, 1999, 22, 852-856.	3.3	32
210	Nitroglycerin enhances cGMP expression in specific neuronal and cerebrovascular structures of the rat brain. Journal of Chemical Neuroanatomy, 2004, 27, 23-32.	2.1	32
211	The Usefulness and Applicability of a Basic Headache Diary Before First Consultation: Results of a Pilot Study Conducted In Two Centres. Cephalalgia, 2008, 28, 1023-1030.	3.9	32
212	Cost of Chronic and Episodic Migraine: a pilot study from a tertiary headache centre in northern Italy. Journal of Headache and Pain, 2015, 16, 532.	6.0	32
213	Naproxen Sodium in the Treatment of Premenstrual Symptoms. Gynecologic and Obstetric Investigation, 1989, 28, 205-208.	1.6	31
214	Nitric Oxide Pathway and Response to Nitroglycerin in Cluster Headache Patients: Plasma Nitrite and Citrulline Levels. Cephalalgia, 2003, 23, 407-413.	3.9	31
215	Central Components of the Analgesic/Antihyperalgesic Effect of Nimesulide. Drugs, 2003, 63, 9-22.	10.9	31
216	Episodic Cluster Headache: NREM Prevalence of Nocturnal Attacks. Time to Look Beyond Macrostructural Analysis?. Headache, 2010, 50, 1050-1054.	3.9	31

#	Article	IF	Citations
217	Evaluation of ADMA-DDAH-NOS axis in specific brain areas following nitroglycerin administration: study in an animal model of migraine. Journal of Headache and Pain, 2015, 16, 560.	6.0	31
218	Changes of biological rhythms in primary headache syndromes. Cephalalgia, 1983, 3, 58-68.	3.9	30
219	Dermorphin inhibits spinal nociceptive flexion reflex in humans. Brain Research, 1986, 371, 364-367.	2.2	30
220	Case-Control Study on the Epidemiology of Cluster Headache I: Etiological Factors and Associated Conditions. Neuroepidemiology, 1995, 14, 123-127.	2.3	30
221	An Italian-Australian comparison of quality of life among people with intellectual disability living in the community. Journal of Intellectual Disability Research, 1999, 43, 513-522.	2.0	30
222	Activation of CB2 receptors as a potential therapeutic target for migraine: evaluation in an animal model. Journal of Headache and Pain, 2014, 15, 14.	6.0	30
223	Clinical and Demographical Characteristics of Patients with Medication Overuse Headache in Argentina and Chile: Analysis of the Latin American Section of COMOESTAS Project. Journal of Headache and Pain, 2015, 16, 83.	6.0	30
224	Effects of nimesulide on nitric oxide-induced hyperalgesia in humans—a neurophysiological study. European Journal of Pharmacology, 2002, 450, 259-262.	3.5	29
225	Nitroglycerin-Induced Activation of Monoaminergic Transmission in the Rat. Cephalalgia, 2002, 22, 226-232.	3.9	29
226	Parenteral Indomethacin (The Indotest) in Cluster Headache. Cephalalgia, 2003, 23, 193-196.	3.9	29
227	$17\hat{l}^2$ -Estradiol Reduces Neuronal Apoptosis Induced by HIV-1 gp120 in the Neocortex of Rat. NeuroToxicology, 2005, 26, 893-903.	3.0	29
228	Different effects of tibolone and low-dose EPT in the management of postmenopausal women with primary headaches. Menopause, 2006, 13, 818-825.	2.0	29
229	Hypertension and migraine comorbidity: prevalence and risk of cerebrovascular events: evidence from a large, multicenter, cross-sectional survey in Italy (MIRACLES study). Journal of Hypertension, 2011, 29, 309-318.	0.5	29
230	Economic benefits of treating medication-overuse headache – results from the multicenter COMOESTAS project. Cephalalgia, 2019, 39, 274-285.	3.9	29
231	Indomethacin increases the effect of isosorbide dinitrate on cerebral hemodynamic in migraine patients: pathogenetic and therapeutic implications. Cephalalgia, 1998, 18, 622-630.	3.9	28
232	Klinische, funktionelle und Änderungen der Lebensqualitäbei Patienten mit Krampfadern nach Thermalbad in schwefelhaltigem Wasser. Vasa - European Journal of Vascular Medicine, 2003, 32, 26-30.	1.4	28
233	Role of central dopaminergic circuitry in pain processing and nitroglycerin-induced hyperalgesia. Brain Research, 2008, 1238, 215-223.	2.2	28
234	Dietary restriction does not prevent nigrostriatal degeneration in the 6-hydroxydopamine model of Parkinson's disease. Experimental Neurology, 2008, 212, 548-551.	4.1	28

#	Article	IF	Citations
235	What do the patients with medication overuse headache expect from treatment and what are the preferred sources of information?. Journal of Headache and Pain, 2011, 12, 91-96.	6.0	28
236	Psychological factors associated with failure of detoxification treatment in chronic headache associated with medication overuse. Cephalalgia, 2016, 36, 1356-1365.	3.9	28
237	When cervical pain is actually migraine: An observational study in 207 patients. Cephalalgia, 2018, 38, 383-388.	3.9	28
238	Endorphin Patterns within the Headache Spectrum Disorders. Cephalalgia, 1985, 5, 201-210.	3.9	27
239	Chronic Daily Headache. How Should it Be Included in the IHS Classification?. Headache, 1999, 39, 197-203.	3.9	27
240	Blockade of subthalamic glutamatergic activity corrects changes in neuronal metabolism and motor behavior in rats with nigrostriatal lesions. Neurological Sciences, 2001, 22, 49-50.	1.9	27
241	Long-Term Evaluation of the Effect of Quetiapine on Hallucinations, Delusions and Motor Function in Advanced Parkinson Disease. Clinical Neuropharmacology, 2004, 27, 33-37.	0.7	27
242	Efficacy of dosing and re-dosing of two oral fixed combinations of indomethacin, prochlorperazine and caffeine compared with oral sumatriptan in the acute treatment of multiple migraine attacks: a double-blind, double-dummy, randomised, parallel group, mu. International Journal of Clinical Practice, 2007, 61, 1256-1269.	1.7	27
243	Chapter 27 Prevention of Glutamate Accumulation and Upregulation of Phosphoâ€Akt may Account for Neuroprotection Afforded by Bergamot Essential Oil against Brain Injury Induced by Focal Cerebral Ischemia in Rat. International Review of Neurobiology, 2009, 85, 389-405.	2.0	27
244	Differences in the Personality Profile of Medication-Overuse Headache Sufferers and Drug Addict Patients: A Comparative Study Using MMPI-2. Headache, 2011, 51, 1212-1227.	3.9	27
245	Factors associated to chronic migraine with medication overuse: A cross-sectional study. Cephalalgia, 2018, 38, 2045-2057.	3.9	27
246	Headache as a Major Public Health Problem: Current Status. Cephalalgia, 1998, 18, 66-69.	3.9	26
247	Vasomotor response to CO2 and L-Arginine in patients with severe internal carotid artery stenosis; pre- and post-surgical evaluation with transcranial Doppler. Journal of the Neurological Sciences, 1999, 163, 153-158.	0.6	26
248	Multicentre Italian family-based association study on tyrosine hydroxylase, catechol-O-methyl transferase and Wolfram syndrome 1 polymorphisms in mood disorders. Psychiatric Genetics, 2003, 13, 121-126.	1.1	26
249	Focus on therapy of the Chapter IV headaches provoked by exertional factors: primary cough headache, primary exertional headache and primary headache associated with sexual activity. Journal of Headache and Pain, 2010, 11, 525-530.	6.0	26
250	Alexithymia in chronic and episodic migraine: a comparative study. Journal of Mental Health, 2017, 26, 192-196.	1.9	26
251	Reserpine - Headache and PRL Release in Migraine. Headache, 1979, 19, 273-277.	3.9	25
252	Pupil Responsiveness in Cluster Headache: A Dynamic TV Pupillometric Evaluation. Cephalalgia, 1988, 8, 193-201.	3.9	25

#	Article	IF	Citations
253	Neuroendocrine changes in luteal function in patients with premenstrual syndrome Journal of Clinical Endocrinology and Metabolism, 1993, 76, 1123-1127.	3.6	25
254	Pain Pressure Threshold in Cluster Headache Patients. Cephalalgia, 1996, 16, 62-66.	3.9	25
255	Gaseous Neurotransmitters in the Hypothalamus. The Roles of Nitric Oxide and Carbon Monoxide in Neuroendocrinology. Hormone and Metabolic Research, 1997, 29, 477-482.	1.5	25
256	Reversible Chorea and Focal Dystonia in Vitamin B12Deficiency. New England Journal of Medicine, 2002, 347, 295-295.	27.0	25
257	The role of rehabilitation in deep brain stimulation of the subthalamic nucleus for Parkinson's disease: A pilot study. Parkinsonism and Related Disorders, 2009, 15, 675-681.	2.2	25
258	An electronic diary on a palm device for headache monitoring: a preliminary experience. Journal of Headache and Pain, 2012, 13, 537-541.	6.0	25
259	New CACNA1A deletions are associated to migraine phenotypes. Journal of Headache and Pain, 2018, 19, 75.	6.0	25
260	Psychological, clinical, and therapeutic predictors of the outcome of detoxification in a large clinical population of medication-overuse headache: A six-month follow-up of the COMOESTAS Project. Cephalalgia, 2019, 39, 135-147.	3.9	25
261	Evaluation of thermal water in patients with functional dyspepsia and irritable bowel syndrome accompanying constipation. World Journal of Gastroenterology, 2006, 12, 2556.	3.3	25
262	Early splenectomy and polychemotherapy versus polychemotherapy alone in chronic myeloid leukemia. Leukemia Research, 1981, 5, 149-157.	0.8	24
263	Plasma Opioid Levels in Post-traumatic Chronic Headache and Trigeminal Neuralgia: Maintained Response to Acupuncture. Headache, 1982, 22, 276-279.	3.9	24
264	Imbalance of heart rate regulation in cluster headache as based on continuous 24-h recordings. Clinical Autonomic Research, 1993, 3, 291-298.	2.5	24
265	Effects of dothiepin on nociceptive flexion reflex and diffuse noxious inhibitory controls in humans. European Journal of Pharmacology, 1993, 243, 99-102.	3.5	24
266	Long-Term Outcome of Migraine. Cephalalgia, 1998, 18, 30-33.	3.9	24
267	lkappaB-alpha expression following transient focal cerebral ischemia is modulated by nitric oxide. Brain Research, 2011, 1372, 145-151.	2.2	24
268	Functional polymorphisms in <scp>COMT</scp> and <scp>SLC</scp> 6A4 genes influence the prognosis of patients with medication overuse headache after withdrawal therapy. European Journal of Neurology, 2014, 21, 989-995.	3.3	24
269	CSF Î ² -EP in Headache and Depression. Cephalalgia, 1985, 5, 99-101.	3.9	23
270	Selective stimulation of striatal dopamine receptors of the D1- or D2-class causes opposite changes of fos expression in the rat cerebral cortex. European Journal of Neuroscience, 2003, 17, 763-770.	2.6	23

#	Article	IF	Citations
271	Migraine-like disorder segregating with mtDNA 14484 Leber hereditary optic neuropathy mutation. Neurology, 2003, 60, 717-719.	1.1	23
272	Effects of sulphurous water on human neutrophil elastase release. Therapeutic Advances in Respiratory Disease, 2010, 4, 333-340.	2.6	23
273	Report of eight new cases of hypnic headache and mini-review of the literature. Functional Neurology, 2002, 17, 211-9.	1.3	23
274	Combined response of plasma and platelet catecholamines to different types of short-term stress. Life Sciences, 1995, 56, 1113-1120.	4.3	22
275	Opposite effects of l-arginine and nitroglycerin on cerebral blood velocity: Nitric oxide precursors and cerebral blood velocity. Journal of the Neurological Sciences, 1997, 150, 71-75.	0.6	22
276	Haemodynamic Correlates of Early and Delayed Responses to Sublingual Administration of Isosorbide Dinitrate in Migraine Patients. Cephalalgia, 1997, 17, 183-187.	3.9	22
277	Premenstrual Syndrome and Anxiety Disorders: A Psychobiological Link. Psychotherapy and Psychosomatics, 1998, 67, 57-60.	8.8	22
278	The prevalence of dementia and cognitive deficit in a rural population of 2442 residents in northern Italy. A door-to-door survey. European Journal of Neurology, 2001, 8, 595-600.	3.3	22
279	Dopaminergic Modulation of Apoptosis in Human Peripheral Blood Mononuclear Cells. Annals of the New York Academy of Sciences, 2003, 1010, 679-682.	3.8	22
280	Enhanced anandamide degradation is associated with neuronal apoptosis induced by the HIV-1 coat glycoprotein gp120 in the rat neocortex. Journal of Neurochemistry, 2004, 89, 1293-1300.	3.9	22
281	Early-onset progressive ataxia associated with the first CACNA1A mutation identified within the l–II loop. Journal of the Neurological Sciences, 2007, 254, 69-71.	0.6	22
282	Cerebrospinal fluid 5-hydroxyindoleacetic acid level in migrainous patients during spontaneous attacks, during headache-free periods and following treatment withl-tryptophan. Experientia, 1974, 30, 640-641.	1.2	21
283	Beta-Endorphin, Beta-Lipotropin and Adrenocorticotropic Hormone Levels in Cerebrospinal Fluid, and Brain Damage in Chronic Alcoholics. European Neurology, 1983, 22, 265-271.	1.4	21
284	Plasma and CSF Endorphin Levels in Primary and Symptomatic Headaches. Headache, 1985, 25, 141-144.	3.9	21
285	Electroretinographic and visual evoked potential abnormalities in myotonic dystrophy. Electroencephalography and Clinical Neurophysiology, 1986, 64, 215-217.	0.3	21
286	Review: Significance of hormonal changes in migraine and cluster headache. Gynecological Endocrinology, 1987, 1, 295-319.	1.7	21
287	Lisuride plus selegiline in the treatment of early Parkinson's disease. Acta Neurologica Scandinavica, 1991, 83, 407-410.	2.1	21
288	Cardiovascular dysautonomia as a cause of falls in Parkinson's disease. Parkinsonism and Related Disorders, 2006, 12, 195-204.	2.2	21

#	Article	IF	Citations
289	Neuroprotective Effect of Nitroglycerin in a Rodent Model of Ischemic Stroke: Evaluation of Bclâ€2 Expression. International Review of Neurobiology, 2007, 82, 423-435.	2.0	21
290	Focus on therapy: hemicrania continua and new daily persistent headache. Journal of Headache and Pain, 2010, 11, 259-265.	6.0	21
291	Neuroendocrine aspects of migraine in women. Gynecological Endocrinology, 2012, 28, 37-41.	1.7	21
292	Premenstrual failure of alpha-adrenergic stimulation on hypothalamus-pituitary responses in menstrual migraine Psychosomatic Medicine, 1989, 51, 550-558.	2.0	20
293	Different effect of high doses of naloxone on spinal reflexes in normal subjects and chronic paraplegic patients. Neuroscience Letters, 1999, 261, 5-8.	2.1	20
294	Comparative analysis of the neuronal activation and cardiovascular effects of nitroglycerin, sodium nitroprusside and l-arginine. Brain Research, 2005, 1051, 17-24.	2.2	20
295	Medical healthcare use in Parkinson's disease: survey in a cohort of ambulatory patients in Italy. BMC Health Services Research, 2005, 5, 26.	2.2	20
296	Headache Attributed to Infection: Observations on the IHS Classification (ICHD-II). Cephalalgia, 2006, 26, 1427-1433.	3.9	20
297	Use of complementary and alternative medicine by patients with cluster headache: Results of a multi-centre headache clinic survey. Complementary Therapies in Medicine, 2008, 16, 220-227.	2.7	20
298	Posatirelin in the treatment of vascular dementia: a double-blind multicentre study vs placebo. Acta Neurologica Scandinavica, 1996, 93, 456-463.	2.1	20
299	Calcium Homeostasis Is Dysregulated in Parkinsonian Patients With I-DOPA-Induced Dyskinesias. Clinical Neuropharmacology, 2009, 32, 133-139.	0.7	20
300	Focus on therapy of hypnic headache. Journal of Headache and Pain, 2010, 11, 349-354.	6.0	20
301	Prolonged migraine aura: new insights from a prospective diary-aided study. Journal of Headache and Pain, 2018, 19, 77.	6.0	20
302	OESTRADIOL/PROGESTERONE IMBALANCE AND THE PREMENSTRUAL SYNDROME. Lancet, The, 1983, 322, 1302.	13.7	19
303	L-5HTP Treatment in Primary Headaches: An Attempt at Clinical Identification of Responsive Patients. Cephalalgia, 1984, 4, 159-165.	3.9	19
304	CSF and plasma levels of pro-opiomelanocortin-related peptides in reversible ischaemic attacks and strokes Journal of Neurology, Neurosurgery and Psychiatry, 1986, 49, 17-21.	1.9	19
305	Evidence of alpha-N-acetyl \hat{l}^2 -endorphin in human cerebrospinal fluid. Brain Research, 1992, 586, 1-5.	2.2	19
306	Hydroxyl radical production in the substantia nigra after 6-hydroxydopamine and hypoxia-reoxygenation. Brain Research, 1998, 813, 18-25.	2.2	19

#	Article	IF	Citations
307	Dietary and nutritional patterns in an elderly rural population in Northern and Southern Italy: (II). Nutritional profiles associated with food behaviours. European Journal of Clinical Nutrition, 2003, 57, 1522-1529.	2.9	19
308	Neurobiological mediators of neuronal apoptosis in experimental neuroAIDS. Toxicology Letters, 2003, 139, 199-206.	0.8	19
309	5-hydroxytryptamine1B receptor and triptan response in migraine, lack of association with common polymorphisms. European Journal of Pharmacology, 2008, 580, 43-47.	3.5	19
310	From drug-induced headache to medication overuse headache. A short epidemiological review, with a focus on Latin American countries. Journal of Headache and Pain, 2009, 10, 71-76.	6.0	19
311	The Antioxidant Activity of Sulphurous Thermal Water Protects against Oxidative DNA Damage: A Comet Assay Investigation. Drug Research, 2013, 63, 198-202.	1.7	19
312	Neuroprotection by the PARP inhibitor PJ34 modulates cerebral and circulating RAGE levels in rats exposed to focal brain ischemia. European Journal of Pharmacology, 2014, 744, 91-97.	3.5	19
313	Triptan use in Italy: Insights from administrative databases. Cephalalgia, 2015, 35, 619-626.	3.9	19
314	Modulation of nociceptive threshold by combined hormonal contraceptives in women with oestrogen-withdrawal migraine attacks: a pilot study. Journal of Headache and Pain, 2016, 17, 70.	6.0	19
315	Impairment of adrenergic-induced proopiomelanocortin-related peptide release in heroin addicts. European Journal of Endocrinology, 1985, 108, 1-5.	3.7	18
316	Neuroendocrine evaluation of central opiate activity in primary headache disorders. Pain, 1988, 34, 29-33.	4.2	18
317	Aging Brain and Dementias: Changes in Central Opioids. European Neurology, 1988, 28, 217-220.	1.4	18
318	mtDNA A3243G MELAS mutation is not associated with multigenerational female migraine. Neurology, 2000, 54, 1005-1007.	1.1	18
319	Neuroendocrine Response to the Serotonin Agonist M-Chlorophenylpiperazine in Women with Menstrual Status migrainosus. Neuroendocrinology, 2003, 78, 52-60.	2.5	18
320	SPA therapy of upper respiratory tract inflammations. European Archives of Oto-Rhino-Laryngology, 2013, 270, 565-570.	1.6	18
321	Combined effect of common gene variants on response to drug withdrawal therapy in medication overuse headache. European Journal of Clinical Pharmacology, 2014, 70, 1195-1202.	1.9	18
322	Association of <scp><i>RAMP</i></scp> <i>1</i> â€ <scp>rs</scp> 7590387 With the Risk of Migraine Transformation Into Medication Overuse Headache. Headache, 2015, 55, 658-668.	3.9	18
323	Changes in anxiety and depression symptoms associated to the outcome of MOH: A post-hoc analysis of the Comoestas Project. Cephalalgia, 2018, 38, 646-654.	3.9	18
324	Comparative Efficacy of Cyclandelate versus Flunarizine in the Prophylactic Treatment of Migraine. Drugs, 1987, 33, 103-109.	10.9	17

#	Article	IF	CITATIONS
325	Long-Term Nicergoline Treatment of Mild to Moderate Senile Dementia. Clinical Drug Investigation, 1997, 13, 308-316.	2.2	17
326	Determination of hydroxyl free radical formation in human platelets using high-performance liquid chromatography with electrochemical detection. Biomedical Applications, 1999, 732, 213-220.	1.7	17
327	Assessing the Relative Incidence of Mitochondrial DNA A3243G in Migraine Without Aura With Maternal Inheritance. Headache, 2000, 40, 568-571.	3.9	17
328	Modulation of RAGE Isoforms Expression in the Brain and Plasma of Rats Exposed to Transient Focal Cerebral Ischemia. Neurochemical Research, 2012, 37, 1508-1516.	3.3	17
329	Effectiveness of Madopar HBS plus Madopar Standard in Patients with Fluctuating Parkinson's Disease: Two Years of Follow-Up. European Neurology, 1990, 30, 319-323.	1.4	16
330	Effectiveness of a Piroxicam Fast Dissolving Formulation Sublingually Administered in the Symptomatic Treatment of Migraine Without Aura. Headache, 1993, 33, 296-300.	3.9	16
331	The influence of gender in the evaluation of platelet and plasma catecholamines. Life Sciences, 1993, 52, 1995-2004.	4.3	16
332	Increased Cerebral Blood Flow Velocity Induced by Cold Pressor Test in Migraine: A Possible Basis for Pathogenesis?. Cephalalgia, 1995, 15, 494-498.	3.9	16
333	Effects of dopaminergic stimulation on peripheral markers of apoptosis: relevance to Parkinson?s disease. Neurological Sciences, 2003, 24, 157-158.	1.9	16
334	Role of 2 Common Variants of 5HT2A Gene in Medication Overuse Headache. Headache, 2010, 50, 1587-1596.	3.9	16
335	Neuroendocrine evidence of deranged noradrenergic activity in chronic migraine. Psychoneuroendocrinology, 1989, 14, 357-363.	2.7	15
336	Neurophysiological Markers of Central and Peripheral Involvement of the Nervous System in HIV-Infection. Clinical EEG (electroencephalography), 1991, 22, 193-198.	0.9	15
337	Effects of Terguride on Anterior Pituitary Function in Parkinsonian Patients Treated with L-Dopa: A Double-Blind Study Versus Placebo. Clinical Neuropharmacology, 1996, 19, 72-80.	0.7	15
338	Uncommon primary headaches. Current Opinion in Neurology, 2006, 19, 299-304.	3.6	15
339	Sleep disorders in Parkinson's disease: facts and new perspectives. Neurological Sciences, 2007, 28, S1-S5.	1.9	15
340	Chronic daily headache. Expert Review of Neurotherapeutics, 2008, 8, 361-384.	2.8	15
341	Focus on the management of thunderclap headache: from nosography to treatment. Journal of Headache and Pain, 2011, 12, 251-258.	6.0	15
342	Clinical Subtypes of Medication Overuse Headache – Findings From a Large Cohort. Headache, 2019, 59, 1481-1491.	3.9	15

#	Article	IF	CITATIONS
343	Dihydroergocryptine in the Treatment of Parkinson's Disease. Clinical Neuropharmacology, 1991, 14, 78-83.	0.7	14
344	Long-term idebenone treatment of vascular and degenerative brain disorders of the elderly. Archives of Gerontology and Geriatrics, 1992, 15, 261-269.	3.0	14
345	Reaction time responses in parkinsonian and hemiparkinsonian patients. Movement Disorders, 1993, 8, 13-18.	3.9	14
346	Dopamine Receptor Agonists Mediate Neuroprotection in Malonate-Induced Striatal Lesion in the Rat. Experimental Neurology, 2002, 178, 301-305.	4.1	14
347	The interplay of two single nucleotide polymorphisms in the CACNA1A gene may contribute to migraine susceptibility. Neuroscience Letters, 2009, 453, 12-15.	2.1	14
348	Focus on therapy of primary stabbing headache. Journal of Headache and Pain, 2010, 11, 157-160.	6.0	14
349	Prevalence and pathophysiology of post-prandial migraine in patients with functional dyspepsia. Cephalalgia, 2019, 39, 1560-1568.	3.9	14
350	Dysregulation of plasma pro-opiomelanocortin-related peptides in neurotic depression. European Journal of Endocrinology, 1986, 112, 1-6.	3.7	13
351	No gradient exists between lumbar and ventricular cerebrospinal fluid \hat{I}^2 -endorphin. Neuroscience Letters, 1987, 77, 349-352.	2.1	13
352	Chronic Paroxysmal Hemicrania: A Chronobiological Study (Case Report). Cephalalgia, 1989, 9, 281-286.	3.9	13
353	Sleep-apnoea and autonomic dysfunction: a cardiopressor and pupillometric study. Acta Neurologica Scandinavica, 1995, 91, 382-388.	2.1	13
354	Sleep attacks in Parkinson?s disease: a clinical and polysomnographic study. Neurological Sciences, 2003, 24, 195-196.	1.9	13
355	Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson?s disease. Journal of Neural Transmission, 2003, 110, 911-922.	2.8	13
356	Effects of homocysteine on apoptosis-related proteins and anti-oxidant systems in isolated human lymphocytes. FEBS Journal, 2004, 271, 1671-1676.	0.2	13
357	Has time come for a re-assessment of spa therapy? The NAIADE survey in Italy. International Journal of Biometeorology, 2008, 52, 231-237.	3.0	13
358	Hemifacial Spasm Associated with Dolichomegavertebrobasilar Anomaly. European Neurology, 1977, 15, 94-101.	1.4	12
359	Dissociation between CSF and plasma B-endorphin in major depressive disorders: evidence for a different regulation. Journal of Endocrinological Investigation, 1986, 9, 11-14.	3.3	12
360	Ritanserin, a Serotonin-S ₂ Receptor Antagonist, Does Not Prevent 5-Hydroxytryptophan-Induced β-EP, β-LPH and Cortisol Secretion. Hormone Research, 1987, 27, 42-46.	1.8	12

#	Article	IF	CITATIONS
361	Cerebrospinal fluid corticotropin-releasing factor levels and stimulation test in dementia of the alzheimer type. Journal of Clinical Laboratory Analysis, 1990, 4, 5-8.	2.1	12
362	Reciprocal circuits involved in nitroglycerin-induced neuronal activation of autonomic regions and pain pathways: a double immunolabeling and tract-tracing study. Brain Research, 1999, 842, 294-310.	2.2	12
363	Focus on trial endpoints of clinical relevance and the use of almotriptan for the acute treatment of migraine. International Journal of Clinical Practice, 2005, 59, 1356-1365.	1.7	12
364	Meeting patient expectations in migraine treatment: what are the key endpoints?. Journal of Headache and Pain, 2008, 9, 207-213.	6.0	12
365	Free radical–scavenging activity of sulfurous water investigated by electron paramagnetic resonance (EPR) spectroscopy. Experimental Lung Research, 2012, 38, 67-74.	1.2	12
366	Circadian rhythmicity of prolactin secretion in Huntington's Chorea. Life Sciences, 1980, 26, 1609-1617.	4.3	11
367	Effects of Lisuride on Blink Reflex Habituation in Parkinson Disease. European Neurology, 1985, 24, 374-379.	1.4	11
368	A multicenter Italian randomised study on early treatment of Parkinson disease: comparison of 1 -dopa, 1 -deprenyl and dopaminoagonists. Study design and short term results. Italian Journal of Neurological Sciences, 1992, 13, 735-739.	0.1	11
369	Combined evaluation of pupillary and cardiovascular responses to cold pressor test in cluster headache patients. Cephalalgia, 1998, 18, 668-674.	3.9	11
370	Parkinson's disease and reproductive life events. Neurological Sciences, 2002, 23, s85-s86.	1.9	11
371	Retinal Migraine as Unusual Feature of Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL). Cephalalgia, 2004, 24, 74-77.	3.9	11
372	A CARE pathway in medication–overuse headache: the experience of the Headache Centre in Pavia. Journal of Headache and Pain, 2005, 6, 307-309.	6.0	11
373	How parkinsonism influences life: the patients' point of view. Neurological Sciences, 2011, 32, 125-131.	1.9	11
374	Association of haplotype combination of serotonin transporter gene polymorphisms with monthly headache days in MOH patients. European Journal of Neurology, 2012, 19, 69-75.	3.3	11
375	Pharmacogenomics of episodic migraine: time has come for a step forward. Pharmacogenomics, 2014, 15, 541-549.	1.3	11
376	A questionnaire on sleep and mental disorders in Parkinson's disease (QSMDPD): development and application of a new screening tool. Functional Neurology, 2004, 19, 83-99.	1.3	11
377	Abnormal dexamethasone suppression test in daily chronic headache sufferers. Psychiatry Research, 1986, 19, 51-57.	3.3	10
378	The trigemino-pupillary reflex: a model of sensory-vegetative integration. Journal of the Autonomic Nervous System, 1992, 41, 179-185.	1.9	10

#	Article	IF	Citations
379	Terguride in fluctuating parkinsonian patients: A double-blind study versus placebo. Movement Disorders, 1993, 8, 463-465.	3.9	10
380	Changes in motoneuron excitability of masseter muscle following exteroceptive stimuli in Parkinson's disease. Electroencephalography and Clinical Neurophysiology - Evoked Potentials, 1993, 89, 29-34.	2.0	10
381	Effects of Etoperidone on Sympathetic and Pituitary-Adrenal Responses to Diverse Stressors in Humans. Clinical Neuropharmacology, 1993, 16, 127-138.	0.7	10
382	The neuroendocrine effects of sumatriptan, a specific ligand for 5-HT1-like receptors. Clinical Endocrinology, 1994, 40, 211-214.	2.4	10
383	Neuroprotective effects mediated by dopamine receptor agonists against malonate-induced lesion in the rat striatum. Neurological Sciences, 2003, 24, 180-181.	1.9	10
384	Bath-Related Headache: The First European Case. Cephalalgia, 2006, 26, 1485-1486.	3.9	10
385	Eletriptan. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 1587-1598.	3.3	10
386	Report of ten years' activity in an Alzheimer's disease assessment unit. Aging Clinical and Experimental Research, 2009, 21, 365-368.	2.9	10
387	Lack of association between GRIA1 polymorphisms and haplotypes with migraine without aura or response to triptans. Neurological Sciences, 2014, 35, 421-427.	1.9	10
388	Effects of L-5HTP With and Without Carbidopa on Plasma \hat{l}^2 -Endorphin and Pain Perception: Possible Implications in Migraine Prophylaxis. Cephalalgia, 1986, 6, 175-179.	3.9	9
389	Disordered Pulsatile Lh Release In Cluster Headache. Cephalalgia, 1987, 7, 79-81.	3.9	9
390	The Trigemino-Pupillary Response in Cluster Headache. Cephalalgia, 1993, 13, 338-342.	3.9	9
391	Quantification of Headache Disability: A Diagnostic-Based Approach. Headache, 1995, 35, 131-137.	3.9	9
392	Neurophysiological approach to central pain modulation in primary headaches. Journal of Headache and Pain, 2005, 6, 191-194.	6.0	9
393	Patients with headache and functional dyspepsia present meal–induced hypersensitivity of the stomach. Journal of Headache and Pain, 2005, 6, 223-226.	6.0	9
394	Botulinum toxin for chronic migraine: Clinical trials and technical aspects. Toxicon, 2018, 147, 111-115.	1.6	9
395	Asymmetrical reduction of the nociceptive flexion reflex threshold in cluster headache. Cephalalgia, 2000, 20, 647-652.	3.9	9
396	Andrographis Paniculata shows anti-nociceptive effects in an animal model of sensory hypersensitivity associated with migraine. Functional Neurology, 2016, 31, 53-60.	1.3	9

#	Article	IF	CITATIONS
397	Cholinesterase inhibitors in Alzheimer's disease: efficacy in a non-selected population. Functional Neurology, 2003, 18, 233-7.	1.3	9
398	Lithium salts in cluster headache treatment. Cephalalgia, 1983, 3, 79-84.	3.9	8
399	N-terminal ACTH fragments increase the CSF \hat{I}^2 -EP content in Alzheimer type dementia. Acta Neurologica Scandinavica, 1988, 78, 146-151.	2.1	8
400	Bilateral Asymmetry of Cerebral Blood Velocity in Cluster Headache. Cephalalgia, 1994, 14, 346-351.	3.9	8
401	Secondary cervical dystonia in iatrogenic hypoparathyroidism associated with extensive brain calcifications. Functional Neurology, 2006, 21, 165-6.	1.3	8
402	Effects of L-5HTP with and Without Carbidopa on Plasma ß-Endorphin and Pain Perception: Possible Implications in Migraine Prophylaxis. Cephalalgia, 1986, 6, 241-245.	3.9	7
403	Lisuride in Menstrual Migraine Prophylaxis. Cephalalgia, 1989, 9, 444-445.	3.9	7
404	Unilateral lesion of the subthalamic nucleus enhances cortical fos expression associated with focally evoked seizures in the rat. Brain Research, 2006, 1101, 145-150.	2.2	7
405	Eletriptan: a review and new perspectives. Expert Review of Neurotherapeutics, 2006, 6, 1413-1421.	2.8	7
406	Is Hemicrania Continua a Single Entity or the Association of Two Headache Forms? Considerations From a Case Report. Headache, 2010, 50, 877-881.	3.9	7
407	Alpha-dihydroergocryptine and predictive factors in migraine prophylaxis. International Journal of Clinical Pharmacology and Therapeutics, 2001, 39, 144-151.	0.6	7
408	Acetyl-L-Carnitine Acutely Administered Raises \hat{l}^2 -Endorphin and Cortisol Plasma Levels in Humans. Clinical Neuropharmacology, 1988, 11, 472-477.	0.7	6
409	Antalgic and Antidepressant Activities of Fluoxetine in Daily Chronic Headache. Cephalalgia, 1991, 11, 280-281.	3.9	6
410	Personality traits in secondary amenorrhea. Journal of Psychosomatic Obstetrics and Gynaecology, 1991, 12, 67-76.	2.1	6
411	Comparison of teniloxazine and piracetam in alzheimer-type or vascular dementia. Current Therapeutic Research, 1995, 56, 250-257.	1.2	6
412	Diagnostic issues in chronic daily headache. Current Pain and Headache Reports, 2001, 5, 551-556.	2.9	6
413	Involvement of a Glutamatergic Mechanism in $\hat{\Gamma}$ -Dendrotoxin-Induced Hippocampal Neuronal Cell Loss in the Rat. Basic and Clinical Pharmacology and Toxicology, 2004, 94, 132-138.	2.5	6
414	Comparative Doppler Directional Sonographic and Ophthalmodynamographic Study in the Occlusion of the Internal Carotid Artery. European Neurology, 1977, 15, 102-108.	1.4	5

#	Article	IF	Citations
415	Insulin receptors in myotonic dystrophy: A study with mononuclear leucocytes and erythrocytes. Italian Journal of Neurological Sciences, 1982, 3, 99-106.	0.1	5
416	Neuroendocrine Data in Chronic Post-traumatic Headache. Headache, 1982, 22, 38-45.	3.9	5
417	Lornoxicam, A New Non-Steroidal Anti-Iflammatory Drug, in Migraine Prophylaxis: A Double-Blind Multicenter Study. Cephalalgia, 1991, 11, 154-155.	3.9	5
418	Cardiopressor Effects of Short-term Treatment With Cabergoline in L-Dopa Stable Responder Parkinsonian Patients. Clinical Neuropharmacology, 1991, 14, 343-351.	0.7	5
419	Preface. Cephalalgia, 1997, 17, 5-5.	3.9	5
420	Cerebral Hemodynamics in Primary Headaches: The Transcranial Doppler Experience. Cephalalgia, 1998, 18, 17-22.	3.9	5
421	Modifications of Local Cerebral Metabolic Rates for Glucose and Motor Behavior in Rats with Unilateral Lesion of the Subthalamic Nucleus. Journal of Cerebral Blood Flow and Metabolism, 1999, 19, 149-154.	4.3	5
422	Implementation and evaluation of existing guidelines on the use of neurophysiological tests in non-acute migraine patients: a questionnaire survey of neurologists and primary care physicians. European Journal of Neurology, 2009, 16, 937-942.	3.3	5
423	Long-Term Efficacy and Safety of Flunarizine in the Prophylaxis of Migraine without Aura. Cephalalgia, 1989, 9, 426-427.	3.9	4
424	Haemodynamic and neurohormonal responsiveness to different stress tests in mitral valve prolapse. Clinical Autonomic Research, 1991, 1, 323-327.	2.5	4
425	Title is missing!. Psychiatric Genetics, 2003, 13, 121-126.	1.1	4
426	Proteasomal inhibition and apoptosis regulatory changes in human isolated lymphocytes: The synergistic role of dopamine. Journal of Cellular Biochemistry, 2008, 103, 877-885.	2.6	4
427	A prospective multicentre study to evaluate the consistency of the IHS diagnostic criteria, the usefulness of brain MRI for the diagnosis, follow-up and treatment management, and the outcome after high dosage 6-methylprednisolone therapy, in subjects with Tolosa–Hunt syndrome. Journal of Headache and Pain, 2010, 11, 285-285.	6.0	4
428	A Case of Late Onset Lipid Storage Myopathy. European Neurology, 1975, 13, 273-284.	1.4	3
429	Naloxone Test In Primary Headache Sufferers. Cephalalgia, 1987, 7, 39-42.	3.9	3
430	Involvement Of Serotonin In The Central Control Of Opioid Secretion. Cephalalgia, 1987, 7, 506-513.	3.9	3
431	A Study of the Cardiopressor Effects of Lisuride in the Treatment of Parkinsonism and Pathological Aging Brain. Clinical Neuropharmacology, 1989, 12, 404-415.	0.7	3
432	Dihydroergokryptine Vs Flunarizine in the Basic Treatment of Migraine without Aura. Cephalalgia, 1991, 11, 216-217.	3.9	3

#	Article	IF	Citations
433	Cluster headache and trigeminal autonomic cephalalgias. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2010, 97, 387-388.	1.8	3
434	Evaluation of central opioid tonus in menstrual migraine. Cephalalgia, 1983, 3, 98-100.	3.9	2
435	Piroxicam- \hat{l}^2 -Cyclodextrin in the Treatment of Headache. Drug Investigation, 1990, 2, 79-85.	0.6	2
436	Evidence for the Impairment of Sensory/Nociceptive Integrative Processes in Cluster Headache. The Trigeminal Reflex. Cephalalgia, 1991, 11, 242-243.	3.9	2
437	Bromocriptine test in the evaluation of patients with syncope of unknown aetiology. Acta Neurologica Scandinavica, 1999, 99, 297-302.	2.1	2
438	Experimental models for the study of cluster headache. Italian Journal of Neurological Sciences, 1999, 20, S21-S24.	0.1	2
439	Neurophysiological approach to the study of cluster headache. Italian Journal of Neurological Sciences, 1999, 20, S31-S33.	0.1	2
440	Neurophysiology of migraine. Journal of Headache and Pain, 2001, 2, s67-s71.	6.0	2
441	Effects of the intrastriatal administration of selective dopaminergic agonists on Fos expression in the rat brain. Neurological Sciences, 2002, 23, s57-s58.	1.9	2
442	Introduction to the new International Classification of Headache Disorders. Journal of Headache and Pain, 2005, 6, 203-204.	6.0	2
443	O011. Patients with "prolonged aura―do not show clinical or demographic differences from the patients with "typical aura― Journal of Headache and Pain, 2015, 16, A67.	6.0	2
444	Neuroendocrinological signs of central neurotransmission disorders. Cephalalgia, 1983, 3, 122-128.	3.9	1
445	USELESS DRUGS?. Lancet, The, 1986, 328, 1217-1218.	13.7	1
446	Sympathergic/Neuroendocrine Reactivity As A Marker Of Adaptive Processes Underlying Migraine Susceptibility. Cephalalgia, 1987, 7, 533-535.	3.9	1
447	Personality Pattern and Analgesic Abuse in Chronic Headache Patients. Cephalalgia, 1989, 9, 246-247.	3.9	1
448	Neurotensin-induced miosis: The role of dopaminergic pathways. Peptides, 1990, 11, 1309-1311.	2.4	1
449	Sumatriptan in the treatment of migraine attacks. Current Therapeutic Research, 1993, 53, 599-602.	1.2	1
450	Post-menopausal changes and dementing illness: Ovarian steroids as the causal link?. Aging Clinical and Experimental Research, 1997, 9, 66-67.	2.9	1

#	Article	lF	CITATIONS
451	Headache Coding and Diagnostic-Related Groups: A Survey of One Year's Admissions to a Neurological Department. Cephalalgia, 1998, 18, 73-75.	3.9	1
452	Primary headaches: Diagnosis and treatment. Current Review of Pain, 1999, 3, 100-108.	0.7	1
453	Reliability of the Nitroglycerin Provocative Test in the Diagnosis of Neurovascular Headaches. Cephalalgia, 2005, 25, 636-637.	3.9	1
454	Reliability of the Nitroglycerin Provocative Test in the Diagnosis of Neurovascular Headaches: Reply. Cephalalgia, 2005, 25, 637-639.	3.9	1
455	www.cefalea.it: the first five years. Journal of Headache and Pain, 2005, 6, 264-267.	6.0	1
456	Selective lesion of the substantia nigra pars reticulata reduces the cortical Fos expression induced by stimulation of striatal D1-like receptors, in the rat. Experimental Neurology, 2006, 200, 240-244.	4.1	1
457	Secondary headaches. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2010, 97, 497-500.	1.8	1
458	Idebenone: a guide to its use in Alzheimer $\hat{E}\frac{1}{4}$ s disease, other age-related cognitive disorders and Friedreich $\hat{E}\frac{1}{4}$ s ataxia. Drugs and Therapy Perspectives, 2010, 26, 1-5.	0.6	1
459	O010. Migraine aura symptoms last for more than one hour in more than one quarter of patients: results from a prospective diary-aided study. Journal of Headache and Pain, 2015, 16, A65.	6.0	1
460	O012. Intra-variability of the characteristics of migraine attacks. Journal of Headache and Pain, 2015, 16, A70.	6.0	1
461	Risk factors in medication overuse headache: A one-year follow-up study. , 2010, , 68-72.		1
462	Chronobiological correlates of headache: three decades on. Functional Neurology, 2014, 29, 213-4.	1.3	1
463	Membrane processes in myotonic dystrophy duringin vitroaging of erythrocytes. Acta Neurologica Scandinavica, 1982, 65, 661-667.	2.1	0
464	Effectiveness of Ritanserin, A Selective Serotonin-S2 Receptor Antagonist in the Treatment of Chronic Headache with Dysthymic Disorder. Cephalalgia, 1989, 9, 371-372.	3.9	0
465	Dihydroergokryptine (DEK) versus Flunarizine (FLU) in Common Migraine. A Multicentre Double-Blind Study. Cephalalgia, 1989, 9, 373-375.	3.9	0
466	Perimenstrual Headache Prophylaxis with Dihydroergokriptine. Cephalalgia, 1991, 11, 199-200.	3.9	0
467	Plasma Glutathione Level in Chronic Headache Drug Abuser Patients. Cephalalgia, 1991, 11, 186-187.	3.9	0
468	Crenokinesitherapy in lower limbs injuries. Pharmacological Research, 1992, 26, 303.	7.1	0

#	Article	IF	CITATIONS
469	Plasma beta-endorphin, cortisol and norepinephrine responses to physical and metabolic stressors in young and elderly humans. Stress and Health, 1992, 8, 1-9.	0.5	O
470	Autonomic failure in the degenerative processes of the central nervous system: a critical reappraisal. Journal of the Autonomic Nervous System, 1993, 43, 39-40.	1.9	0
471	Carotid Plaques and Multiple Brain Infarctions. Journal of Neuroimaging, 1993, 3, 220-224.	2.0	O
472	Free Communications (Section D). Journal of Neuroimaging, 1995, 5, s88.	2.0	0
473	Pituitary-adrenal responses to dexamethasone and CRH administration in patients with untreated Parkinson's disease. Aging Clinical and Experimental Research, 1997, 9, 69-70.	2.9	0
474	Reducing the costs of headache: an Italian approach. Journal of Headache and Pain, 2003, 4, s75-s76.	6.0	0
475	Potential therapeutic usefulness of hydrogen peroxide in conditions of brain ischemia. Medical Hypotheses, 2008, 71, 162.	1.5	0
476	Other primary headaches $\hat{a} \in \text{``general aspects.}$ Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2010, 97, 451.	1.8	0
477	Preface. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2010, 97, ix-x.	1.8	0
478	Rehabilitation from symptomatic drugs overuse: yes, no, may be. Journal of Headache and Pain, 2015, 16, A34.	6.0	0
479	Risposta vasomotoria cerebrale alla stimolazione con CO2 e L-Arginina. The Neuroradiology Journal, 1996, 9, 143-151.	0.1	0
480	Cerebrovascular diseases at the C. Mondino National Institute of Neurology: from Ottorino Rossi to the present day. Functional Neurology, 2011, 26, 87-95.	1.3	0